Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Rituximab, and Lenalidomide for R/R DLBCL and PCNSL
NCT03558750Phase 1Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jun 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and lenalidomide in diffuse large B-cell lymphoma (DLBCL) and primary central nervous system lymphoma (PCNSL), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Dose Limiting Toxicity and Overall Response Rate. Started Jun 2018; status: terminated.
02
Drugs
nivolumablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT03558750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558750.